Nakamura S, Sakurada S, Salahuddin S Z, Osada Y, Tanaka N G, Sakamoto N, Sekiguchi M, Gallo R C
Department of Internal Medicine, University of Southern California, Los Angeles 90033.
Science. 1992 Mar 13;255(5050):1437-40. doi: 10.1126/science.1371891.
In vitro and in vivo model systems for the study of human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS) were used to evaluate compounds for their potential as therapeutic agents. A sulfated polysaccharide-peptidoglycan compound (SP-PG) produced by bacteria controlled the in vitro growth of acquired immunodeficiency syndrome (AIDS)-associated, KS-derived spindle-shaped cells (AIDS-KS cells) at noncytotoxic concentrations. Angiogenesis induced by AIDS-KS cells in the chicken chorioallantoic membrane assay was blocked by SP-PG, which also inhibited the vascular hyperpermeability response and the angiogenesis associated with the induction of KS-like lesions that develop after subcutaneous inoculation of AIDS-KS cells into nude mice. Suramin, pentosan polysulfate, and interferon alpha, which are currently in use for therapy of KS, were either less effective than SP-PG or much more cytotoxic, or both.
用于研究人类免疫缺陷病毒（HIV）相关卡波西肉瘤（KS）的体外和体内模型系统被用于评估化合物作为治疗剂的潜力。一种由细菌产生的硫酸化多糖-肽聚糖化合物（SP-PG）在无细胞毒性浓度下可控制获得性免疫缺陷综合征（AIDS）相关的KS来源梭形细胞（AIDS-KS细胞）的体外生长。在鸡胚绒毛尿囊膜试验中，AIDS-KS细胞诱导的血管生成被SP-PG阻断，SP-PG还抑制了血管通透性增加反应以及与将AIDS-KS细胞皮下接种到裸鼠后形成的KS样病变诱导相关的血管生成。目前用于治疗KS的苏拉明、戊聚糖多硫酸盐和α干扰素，要么比SP-PG效果差，要么细胞毒性大得多，或者两者兼具。
